Dose‐ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti‐cancer chemotherapy Journal Article
| Authors: | Pisters, K. M. W.; Kris, M. G.; Tyson, L. B.; Clark, R. A.; Gralla, R. J. |
| Article Title: | Dose‐ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti‐cancer chemotherapy |
| Abstract: | Background. Tropisetron (ICS 205–930) antagonizes the serotonin type 3 receptor and has antiemetic activity in animals given cisplatin. Its mean serum half‐life is 11.1 hours. Methods. In this dose‐ranging trial, 22 patients undergoing anti‐cancer chemotherapy received 24 courses of a single intravenous infusion of tropisetron beginning 30 minutes before chemotherapy. Four dose levels were explored (range, 12–48 mg/m2). Results. Toxicities were mild and included headache, transient elevations of serum alanine transaminase and/or aspartate transaminase levels, and sedation. No akathisia or acute dystonic reactions were observed. Thirty‐six percent of patients had no emesis, and 58% had two or fewer emetic episodes. Ten patients received high‐dose cisplatin (dose, ⩾ 100 mg/m2) as initial chemotherapy. Of these, 30% had no emesis, and 60% had two or fewer episodes. Conclusions. Tropisetron can be administered safely in the doses tested with no dose‐limiting toxicities. The encouraging antiemetic efficacy, mild toxicities, lack of extrapyramidal effects, and convenience of a single 15‐minute infusion regimen make this drug appropriate for study in additional trials. Cancer 1993; 71:226‐30. Copyright © 1993 American Cancer Society |
| Keywords: | adult; cancer chemotherapy; clinical article; aged; cisplatin; doxorubicin; diarrhea; antineoplastic agents; methotrexate; dacarbazine; vomiting; sedation; cyclophosphamide; lomustine; vinblastine; alanine aminotransferase blood level; aspartate aminotransferase blood level; serotonin antagonist; nausea and vomiting; headache; indoles; mitomycin; infusions, intravenous; abdominal cramp; dose calculation; intravenous drug administration; middle age; tropisetron; serotonin antagonists; serotonin 3 receptor; antiemetic activity; human; male; female; priority journal; article; emesis; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; antiemetic; ics 205–930 |
| Journal Title: | Cancer |
| Volume: | 71 |
| Issue: | 1 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 1993-01-01 |
| Start Page: | 226 |
| End Page: | 230 |
| Language: | English |
| DOI: | 10.1002/1097-0142(19930101)71:1<226::Aid-cncr2820710135>3.0.Co;2-t |
| PUBMED: | 8416720 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work